ES2164914T3 - Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. - Google Patents

Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.

Info

Publication number
ES2164914T3
ES2164914T3 ES96929318T ES96929318T ES2164914T3 ES 2164914 T3 ES2164914 T3 ES 2164914T3 ES 96929318 T ES96929318 T ES 96929318T ES 96929318 T ES96929318 T ES 96929318T ES 2164914 T3 ES2164914 T3 ES 2164914T3
Authority
ES
Spain
Prior art keywords
patient
immunotherapy
treat
containing antibodies
specifically detect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96929318T
Other languages
English (en)
Inventor
Horst Lindhofer
Stefan Thierfelder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Application granted granted Critical
Publication of ES2164914T3 publication Critical patent/ES2164914T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN MEDICAMENTOS QUE CONTIENEN ANTICUERPOS CON AL MENOS UNA ESPECIFICIDAD Y QUE RECONOCEN EL ANTIGENO MHCII DE UN PACIENTE A TRATAR. ADEMAS, SE DESCRIBEN ANTICUERPOS CON DOS O MAS ESPECIFICIDADES, QUE RECONOCEN EL ANTIGENO MHCII DE UN PACIENTE, ASI COMO LAS COMPOSICIONES DIAGNOSTICAS QUE CONTIENEN ESTOS.
ES96929318T 1995-08-25 1996-08-23 Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. Expired - Lifetime ES2164914T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531346A DE19531346A1 (de) 1995-08-25 1995-08-25 Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen

Publications (1)

Publication Number Publication Date
ES2164914T3 true ES2164914T3 (es) 2002-03-01

Family

ID=7770409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96929318T Expired - Lifetime ES2164914T3 (es) 1995-08-25 1996-08-23 Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.

Country Status (8)

Country Link
US (1) US6294167B1 (es)
EP (1) EP0845998B1 (es)
AT (1) ATE208630T1 (es)
DE (2) DE19531346A1 (es)
DK (1) DK0845998T3 (es)
ES (1) ES2164914T3 (es)
PT (1) PT845998E (es)
WO (1) WO1997007819A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
DE19937264A1 (de) * 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US20030086929A1 (en) * 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
GB0509318D0 (en) * 2005-05-06 2005-06-15 Chiron Srl TCR-independent activation of T cells
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US7862813B2 (en) * 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
EP2241576A1 (en) 2009-04-17 2010-10-20 Trion Pharma Gmbh Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
CA2940579A1 (en) * 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Also Published As

Publication number Publication date
EP0845998A1 (de) 1998-06-10
DE59608213D1 (de) 2001-12-20
ATE208630T1 (de) 2001-11-15
EP0845998B1 (de) 2001-11-14
DE19531346A1 (de) 1997-02-27
DK0845998T3 (da) 2002-02-11
WO1997007819A1 (de) 1997-03-06
PT845998E (pt) 2002-04-29
US6294167B1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
GB2301366B (en) Antibodies against E-selectin
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
SE9301951D0 (sv) Methods for administration of taxol
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
GR3026219T3 (en) Mouse monoclonal antibodies
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
AR004360A1 (es) Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
ES2173334T3 (es) Composiciones que contienen bismuto, para la prevencion y tratamiento de trastornos gastrointestinales.
TR199901998T2 (xx) 9,10-sekokolesta-5,7,10(19)-triyen-1,3-diyol veya alfakasidol�n kullan�m�.
DK0500921T3 (da) Na-K-ATPase-inhiberende natriuretiske substanser
UA40213A (uk) Спосіб індивідуальної оцінки ефективності сорбенту
ATE205470T1 (de) Fluoriertes propranolol und ahnliche verfahren
KR970005296A (ko) 편도선염 치료제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 845998

Country of ref document: ES